Despite HER2-low expressing breast cancer, which includes tumors that do not meet the criteria for high HER2 expression but still show some level of HER2 protein, comprising about 50% of all breast cancer cases, the clinical significance of this category has been historically underexplored [5]. This evidence concerns the gene ERBB2 and breast carcinoma.